Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Transplantation and Cellular Therapy|May 22, 2022
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple MyelomaScott R Solomon, Stacey Brown, Nancy Shegda, et al.
Blood Advances|October 27, 2020
Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamideScott R Solomon, Michael T Aubrey, Xu Zhang, et al.
Bone Marrow Transplantation|March 11, 2018
Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or olderZain A Bashey, Xu Zhang, Stacey Brown, et al.
Bone Marrow Transplantation|December 7, 2018
Safety and efficacy of rituximab-based first line treatment of chronic GVHDScott R Solomon, Connie A Sizemore, Michelle Ridgeway, et al.
Transplantation and Cellular Therapy|June 15, 2024
Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based TransplantationScott R Solomon, Lizamarie Bachier-Rodriguez, Asad Bashey, et al.
Leukemia & Lymphoma|February 28, 2020
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemiaGail J Roboz, Melissa L Larson, S Eric Rubenstein, et al.
Blood Advances|June 28, 2023
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplantScott R Solomon, Melhem Solh, Lawrence E Morris, et al.
Bone Marrow Transplantation|July 31, 2024
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantationMelhem Solh, Michael T Aubrey, Xu Zhang, et al.
Transplantation and Cellular Therapy|July 5, 2022
Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR LigandScott R Solomon, Michael T Aubrey, Xu Zhang, et al.
Transplantation and Cellular Therapy|April 1, 2024
Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical TransplantScott R Solomon, Michael T Aubrey, Lizamarie Bachier-Rodriguez, et al.
Pageof 8